Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842254 · ClinicalTrials.gov registry record · Early Phase 1
Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease
A Early Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03842254 is a Early Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 6 participants.
The verdict
NCT03842254, a Early Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study evaluates the effect of erythropoietin on the number and function of regulatory T cells in adults with autoimmune hepatitis. Participants will receive a single dose of erythropoietin, and then the investigators will collect blood at different time points for analysis of regulatory T cell number and function.
Interventions
- DRUG Erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2021-02-18 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03842254
The ClinicalTrials.gov registry entry for NCT03842254 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erythropoietin is the first listed.
NCT03842254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03842254 about?
NCT03842254 is a clinical study titled "Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease". This study evaluates the effect of erythropoietin on the number and function of regulatory T cells in adults with autoimmune hepatitis. Participants will receive a single dose of erythropoietin, and then the investigators will collect blood at different time points for analysis of regulatory T cell ...
What is the current status of trial NCT03842254?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2019-01-25. Estimated completion is 2021-02-18.
What interventions are being tested in trial NCT03842254?
The interventions under investigation include: Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT03842254?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.